Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne
Abstract Purpose Tumor protein p53 (TP53) pathogenic variant (PV) carriers are identified during genetic testing for hereditary causes of cancer. PVs in TP53 are associated with the Li‐Fraumeni syndrome (LFS), and thus, surveillance and preventive measures are important for TP53 PV carriers. However...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-02-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6920 |
| _version_ | 1797216958715789312 |
|---|---|
| author | K. Kast K. Rhiem M. Larsen B. Wappenschmidt R. Schmutzler |
| author_facet | K. Kast K. Rhiem M. Larsen B. Wappenschmidt R. Schmutzler |
| author_sort | K. Kast |
| collection | DOAJ |
| description | Abstract Purpose Tumor protein p53 (TP53) pathogenic variant (PV) carriers are identified during genetic testing for hereditary causes of cancer. PVs in TP53 are associated with the Li‐Fraumeni syndrome (LFS), and thus, surveillance and preventive measures are important for TP53 PV carriers. However, the penetrance of TP53 PVs can be low if the Chompret criteria are not fulfilled. In this study, we compared the phenotypic characteristics of families that did and did not fulfill the LFS criteria according to Chompret. Methods The German Consortium for Hereditary Breast and Ovarian Cancer (GC‐HBOC) database was used to identify index patients with a likely pathogenic/pathogenic TP53 variant and their family members. The study investigated the type of variant, pedigree, age of onset, number of primary tumors, and histological type of BC. Results TP53 PV were present in the index cases of 35 families, 57% (20/35) of which fulfilled the Chompret criteria. The median age of onset at first BC diagnosis was lower in families that fulfilled the Chompret criteria compared to those who did not. Four of all diseased individuals were minors (4%; 4/105) when malignancy was first diagnosed. Sarcomas and brain tumors occurred in 10% (10/105) and in 7% (7/105) of all diseased persons, respectively. BC was the most frequently occurring first tumor (60%; 62/105) and additional malignancy (45%; 20/44) in this cohort. Subsequent malignancies developed in 31% (20/65) of the individuals who fulfilled the Chompret criteria compared with 15% (6/40) of those who did not. Conclusion The tumor spectrum and age of onset found in this study showed that tumors other than BC had low disease penetrance in TP53 PV carriers identified using the GC‐HBOC criteria for genetic testing. |
| first_indexed | 2024-03-07T15:43:24Z |
| format | Article |
| id | doaj.art-38956cb111644bab99013a93eb514293 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-24T11:54:14Z |
| publishDate | 2024-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-38956cb111644bab99013a93eb5142932024-04-09T05:45:47ZengWileyCancer Medicine2045-76342024-02-01133n/an/a10.1002/cam4.6920Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, CologneK. Kast0K. Rhiem1M. Larsen2B. Wappenschmidt3R. Schmutzler4Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty University Hospital Cologne Cologne GermanyCenter for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty University Hospital Cologne Cologne GermanyCenter for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty University Hospital Cologne Cologne GermanyCenter for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty University Hospital Cologne Cologne GermanyCenter for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty University Hospital Cologne Cologne GermanyAbstract Purpose Tumor protein p53 (TP53) pathogenic variant (PV) carriers are identified during genetic testing for hereditary causes of cancer. PVs in TP53 are associated with the Li‐Fraumeni syndrome (LFS), and thus, surveillance and preventive measures are important for TP53 PV carriers. However, the penetrance of TP53 PVs can be low if the Chompret criteria are not fulfilled. In this study, we compared the phenotypic characteristics of families that did and did not fulfill the LFS criteria according to Chompret. Methods The German Consortium for Hereditary Breast and Ovarian Cancer (GC‐HBOC) database was used to identify index patients with a likely pathogenic/pathogenic TP53 variant and their family members. The study investigated the type of variant, pedigree, age of onset, number of primary tumors, and histological type of BC. Results TP53 PV were present in the index cases of 35 families, 57% (20/35) of which fulfilled the Chompret criteria. The median age of onset at first BC diagnosis was lower in families that fulfilled the Chompret criteria compared to those who did not. Four of all diseased individuals were minors (4%; 4/105) when malignancy was first diagnosed. Sarcomas and brain tumors occurred in 10% (10/105) and in 7% (7/105) of all diseased persons, respectively. BC was the most frequently occurring first tumor (60%; 62/105) and additional malignancy (45%; 20/44) in this cohort. Subsequent malignancies developed in 31% (20/65) of the individuals who fulfilled the Chompret criteria compared with 15% (6/40) of those who did not. Conclusion The tumor spectrum and age of onset found in this study showed that tumors other than BC had low disease penetrance in TP53 PV carriers identified using the GC‐HBOC criteria for genetic testing.https://doi.org/10.1002/cam4.6920breast cancercancer preventiongenetic variantsnext‐generation sequencing |
| spellingShingle | K. Kast K. Rhiem M. Larsen B. Wappenschmidt R. Schmutzler Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne Cancer Medicine breast cancer cancer prevention genetic variants next‐generation sequencing |
| title | Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne |
| title_full | Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne |
| title_fullStr | Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne |
| title_full_unstemmed | Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne |
| title_short | Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne |
| title_sort | phenotype analysis of families with tp53 germline variants at the center for familial breast and ovarian cancer cologne |
| topic | breast cancer cancer prevention genetic variants next‐generation sequencing |
| url | https://doi.org/10.1002/cam4.6920 |
| work_keys_str_mv | AT kkast phenotypeanalysisoffamilieswithtp53germlinevariantsatthecenterforfamilialbreastandovariancancercologne AT krhiem phenotypeanalysisoffamilieswithtp53germlinevariantsatthecenterforfamilialbreastandovariancancercologne AT mlarsen phenotypeanalysisoffamilieswithtp53germlinevariantsatthecenterforfamilialbreastandovariancancercologne AT bwappenschmidt phenotypeanalysisoffamilieswithtp53germlinevariantsatthecenterforfamilialbreastandovariancancercologne AT rschmutzler phenotypeanalysisoffamilieswithtp53germlinevariantsatthecenterforfamilialbreastandovariancancercologne |